EUVIMEDEUVIMED entdecken
Crossref

A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma

Huiling Song, Haosheng Li, Xiaonan Shen, Kuai Liu, Haoran Feng, Jiahua Cui, Wei Wei, Xiaolu Sun, Qiong Fan, Wei Bao, Haiyan Zhou, Liheng Qian und 3 weitere

Acta Biomaterialia · 2024

DOI: 10.1016/j.actbio.2024.01.047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2024. Verfasst von Huiling Song und 14 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchu…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Royal Society, National Natural Science Foundation of China, Shanghai Jiao Tong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cetuximab (Cet) and oxaliplatin (OXA) are used as first-line drugs for patients with colorectal carcinoma (CRC). In fact, the heterogeneity of CRC, mainly caused by K-ras mutations and drug resistance, undermines the effectiveness of drugs. Recently, a hydrophobic prodrug, (1E,4E)-6-((S)-1-(isopentyloxy)-4-methylpent-3-en-1-yl)-5,8-dimethoxynaphthalene-1,4‑dione dioxime (DMAKO-20), has been shown to undergo tumor-specific CYP1B1-catalyzed bioactivation. This process results in the production of nitric oxide and active naphthoquinone mono-oximes, which exhibit specific antitumor activity against drug-resistant CRC. In this study, a Cet-conjugated bioresponsive DMAKO-20/PCL-PEOz-targeted nanocodelivery system (DMAKO@PCL-PEOz-Cet) was constructed to address the issue of DMAKO-20 dissolution and achieve multitargeted delivery of the cargoes to different subtypes of CRC cells to overcome K-ras mutations and drug resistance in CRC. The experimental results demonstrated that DMAKO@PCL-PEOz-Cet efficiently delivered DMAKO-20 to both K-ras mutant and wild-type CRC cells by targeting the epidermal growth factor receptor (EGFR). It exhibited a higher anticancer effect than OXA in K-ras mutant cells and drug-resistant cells. Additionally, it was observed that DMAKO@PCL-PEOz-Cet reduced the expression of glutathione peroxidase 4 (GPX4) in CRC cells and significantly inhibited the growth of heterogeneous HCT-116 subcutaneous tumors and patient-derived tumor xenografts (PDX) model tumors. This work provides a new strategy for the development of safe and effective approaches for treating CRC. STATEMENT OF SIGNIFICANCE: (1) Significance: This work reports a new approach for the treatment of colorectal carcinoma (CRC) using the bioresponsible Cet-conjugated PCL-PEOz/DMAKO-20 nanodelivery system (DMAKO@PCL-PEOz-Cet) prepared with Cet and PCL-PEOz for the targeted transfer of DMAKO-20, which is an anticancer multitarget drug that can even prevent drug resistance, to wild-type and K-ras mutant CRC cells. DMAKO@PCL-PEOz-Cet, in the form of nanocrystal micelles, maintained stability in peripheral blood and efficiently transported DMAKO-20 to various subtypes of colorectal carcinoma cells, overcoming the challenges posed by K-ras mutations and drug resistance. The system's secure and effective delivery capabilities have also been confirmed in organoid and PDX models. (2) This is the first report demonstrating that this approach simultaneously overcomes the K-ras mutation and drug resistance of CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsHumansCetuximabNanoparticle Drug Delivery SystemCell Line, TumorOxaliplatinDrug Resistance, NeoplasmMutationHydrogen-Ion Concentration

Stichwörter der Autor:innen

Cetuximab-conjugated micellesColorectal carcinomaDMAKO-20Drug resistanceEGFRK-ras mutations

Substanzen

CetuximabNanoparticle Drug Delivery SystemAntineoplastic AgentsOxaliplatin

Autor:innen und Institutionen

  • Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China.
  • Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China; Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong…
  • Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai 200025, China.
  • School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China.
  • The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, 910 Hengshan Road, Shanghai 200030, China.
  • Department of Obstetrics and Gynecology, Shanghai General Hospital affiliated with Shanghai Jiao Tong University, 100 Haining Road, Shanghai 200080, China.

Förderung

  • Royal Society
  • National Natural Science Foundation of China
  • Shanghai Jiao Tong University

Zitieren

APA

Song, H., Li, H., Shen, X., Liu, K., Feng, H., Cui, J., Wei, W., Sun, X., Fan, Q., Bao, W., Zhou, H., Qian, L., Nie, H., Cheng, X., & Du, Z. (2024). A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2024.01.047

Vancouver

Song H, Li H, Shen X, Liu K, Feng H, Cui J, et al. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma. Acta Biomaterialia. 2024. doi:10.1016/j.actbio.2024.01.047

BibTeX
@article{Song2024,
  author = {Song, Huiling and Li, Haosheng and Shen, Xiaonan and Liu, Kuai and Feng, Haoran and Cui, Jiahua and Wei, Wei and Sun, Xiaolu and Fan, Qiong and Bao, Wei and Zhou, Haiyan and Qian, Liheng and Nie, Huizhen and Cheng, Xi and Du, Zixiu},
  title = {A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma},
  journal = {Acta Biomaterialia},
  year = {2024},
  doi = {10.1016/j.actbio.2024.01.047}
}
Kostenlos starten →